Endocrine Abstracts

Glioblastoma (GBM; grade IV astrocytoma) is the one of the most malignant and lethal endocrine-related cancers worldwide. Current standard treatment consists of surgery followed by radiotherapy and/or chemotherapy; however, this is only a palliative approach with a mean post-operative survival of scarcely ~12-15 months. Therefore, the identification of novel therapeutic targets to treat this devastating pathology is urgently needed. In this context, the truncated splicing-vari...